# Engineered targeted Ce-based MOF nanozymes for ROS scavenging and inflammatory Reprogramming in chronic pancreatitis

**Authors:** Yongkang Lai, Yongliang Ouyang, Xiaojing Yin, Tao Yu, Jianhua Wan, Xueyang Li, Yi Hu, Xu Shu, Huan Wang

PMC · DOI: 10.1016/j.mtbio.2026.102811 · 2026-01-21

## TL;DR

Researchers developed a nanosystem to target and reduce inflammation in chronic pancreatitis by scavenging harmful molecules and suppressing inflammation.

## Contribution

A novel Ce-based MOF nanozyme system is introduced for targeted ROS scavenging and inflammation modulation in chronic pancreatitis.

## Key findings

- HC@CeMOF nanosystem effectively scavenges ROS through Ce3+/Ce4+ redox cycling.
- Curcumin release from HC@CeMOF suppresses NF-κB signaling and reduces inflammatory cytokines.
- The nanosystem shows favorable safety and accumulates selectively in inflamed pancreatic tissue.

## Abstract

Chronic pancreatitis (CP) is a lifelong progressive fibrotic inflammatory disorder for which no effective cure is currently available. Persistent and recurrent inflammatory stimulation induced by reactive oxygen species (ROS) is a key driver of pancreatic fibrogenesis, making oxidative stress a promising therapeutic target to halt disease progression. In this study, we developed a nanosystem, HC@CeMOF, consisting of a small-sized cerium-based metal–organic framework (CeMOF) core loaded with curcumin and coated with hyaluronic acid (HA), enabling precise targeting of inflamed pancreatic tissue. HC@CeMOF exhibits a small-sized particle size along with favorable cellular and biological safety profiles. Once administered in vivo, the nanosystem exploits the specific binding affinity of HA to CD44 receptors on macrophages to selectively accumulate at inflamed pancreatic sites. Subsequently, the cerium-based nanozyme efficiently scavenges ROS through the reversible redox cycling between Ce3+ and Ce4+, while the slow release of curcumin further suppresses the NF-κB signaling pathway and modulates inflammatory cytokine levels, thereby achieving synergistic anti-inflammatory and antioxidant effects. Collectively, these mechanisms substantially attenuate CP progression. This targeted ROS-scavenging and anti-inflammatory strategy holds promise as an alternative therapeutic approach for chronic pancreatitis.

Image 1

## Linked entities

- **Proteins:** CD44 (CD44 molecule (IN blood group)), NFKB1 (nuclear factor kappa B subunit 1)
- **Chemicals:** curcumin (PubChem CID 969516), Ce3+ (PubChem CID 114853), Ce4+ (PubChem CID 119438)
- **Diseases:** chronic pancreatitis (MONDO:0005003)

## Full-text entities

- **Genes:** CD44 (CD44 molecule (IN blood group)) [NCBI Gene 960] {aka CDW44, CSPG8, ECM-III, ECMR-III, H-CAM, HCELL}, NFKB1 (nuclear factor kappa B subunit 1) [NCBI Gene 4790] {aka CVID12, EBP-1, KBF1, NF-kB, NF-kB1, NF-kappa-B1}
- **Diseases:** inflammatory (MESH:D007249), CP (MESH:D050500), pancreatic fibrogenesis (MESH:D010195)
- **Chemicals:** HA (MESH:D006820), curcumin (MESH:D003474), ROS (MESH:D017382), metal (MESH:D008670), Ce3+ (-), Ce (MESH:D002563), MOF (MESH:C037042)

## Figures

9 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12874320/full.md

---
Source: https://tomesphere.com/paper/PMC12874320